cevostamab (bfcr4350a): a novel bispecific antibody in r/r myeloma therapy
Published 3 years ago • 93 plays • Length 1:56
Download video MP4
Download video MP3
Similar videos
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
1:38
the efficacy of cevostamab in r/r multiple myeloma and the importance of bispecific antibodies
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
1:37
immune strategies in consolidation and maintenance for multiple myeloma
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
3:30
sc vs. iv administration of a bcma-cd3 bispecific antibody for r/r myeloma
-
4:15
talquetamab: gprc5d-cd3 bispecific antibody in r/r myeloma
-
4:17
evaluating the safety and efficacy of elranatamab in multiple myeloma
-
4:13
real-world study determining the safety and efficacy of teclistamab in r/r multiple myeloma
-
1:47
real-world safety and efficacy of talquetamab for the treatment of r/r myeloma
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
3:23
updated safety and efficacy results of abbv-383, a novel bsab, in patients with r/r multiple myeloma
-
2:02
alnuctamab, a bcma x cd3 tce, in the treatment of multiple myeloma
-
2:25
first-in-human study of talquetamab: a gprc5d-cd3 bispecific antibody for r/r mm
-
6:27
clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma
-
1:21
sequencing of bcma-directed therapies for multiple myeloma
Clip.africa.com - Privacy-policy